INKT
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- MiNK Therapeutics presented early observations from its ongoing Phase 2 trial at the 2026 Military Health System Research SymposiumAug 7, 2026
- MiNK Therapeutics dosed the first patient in a Phase 2 trial of agenT-797 for acute lung injuryMay 29, 2026
- MiNK Therapeutics and First Lviv Territorial Medical Union initiated a randomized Phase 2 trial of agenT-797 for acute lung injury and critical illnessMay 14, 2026
- MiNK Therapeutics partnered with C-Further to develop PRAME-targeted iNKT cell therapy for pediatric cancersMar 10, 2026
- MiNK Therapeutics announces new data showing MiNK-215 drives potent anti-tumor activity in treatment-resistant solid tumorsNov 21, 2025